Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
The medtech market’s fast growth and unfettered demand attracts investment groups, while hospital suppliers consolidate.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.